Compare BridgeBio Pharma Inc (BBIO) vs TKO Group Holdings Inc (TKO) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

TKO trades at $186.56, down 0.39% on the day, with a bullish technical signal and strong analyst support. The company reported record Q2 2026 revenue of $1.55 billion (up 18% year-over-year) and raised full-year guidance, though it missed EPS estimates. Valuation ratios are elevated with a P/E of 66.46, but profitability metrics show improvement. Recent corporate actions include an $800 million share repurchase and a $0.79 dividend payment.

The outlook is positive driven by media rights growth and live events, with a consensus price target of $228.17 implying 22% upside. Risks include earnings volatility and institutional selling. Wall Street sentiment remains strongly bullish with 89% buy ratings.